Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCosts of second-generation antihistamines in the treatment of allergic rhinitis: US perspective
Current Medical Research and Opinion, 06/26/09
Hay JW et al. - Preliminary evidence suggests that newer SGAs offer clinical, pharmacodynamic, and pharmacokinetic advantages that may translate into superior cost-effectiveness in the treatment of AR. Further study is warranted to clarify the pharmacoeconomic impact of the newer SGAs and to establish their relative cost-effectiveness.
Joel W. Hay, 07/13/09
| The direct costs associated with allergic rhinitis (AR) exceeded $11 billion in 2005, with nearly 60% of the total expenditure spent on prescription medications. The majority of individuals with AR in the U.S. are treated with antihistamines; approximately two thirds of those use first-generation antihistamines (FGAs) and one third uses second-generation antihistamines (SGAs). Although less expensive per unit use, FGAs may actually result in increased overall medical expenditures compared with SGAs owing to lost productivity and increased emergency department visits related to adverse events. Our recent literature review demonstrates that SGAs offer clinical, pharmacodynamic, and pharmacokinetic advantages that may translate into greater cost-effectiveness in the treatment of AR. Further study is warranted to clarify the pharmacoeconomic impact of SGAs and to establish their relative cost-effectiveness over FGAs. Current managed care policies that restrict the use of prescription vs. over-the-counter SGAs should be reexamined for cost-effectiveness. |
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Safety and efficacy of testosterone gel in the treatment of male hypogonadism
Clinical Interventions in Aging, 10/12/09
Biphasic effects of hormone treatment on risk of cardiovascular disease
Sexuality, Reproduction & Menopause, 10/20/09
Today in Pharmacoeconomics...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. A Cost-Effectiveness Analysis
Annals of Internal Medicine, 11/03/09
Use and cost of branded and generic drugs in patients with coronary heart disease-results from a prospective survey of 1008 patients in two London hospitals
QJM: An International Journal of Medicine, 10/16/09
Clinical and Economic Comparison of Frovatriptan Versus other Oral Triptans in the Treatment of Acute Migraine in the Real-World Setting
Clinical Drug Investigation, 10/15/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Pediatric antifungal agents
Current Opinion in Infectious Diseases, 10/28/09
Pharmacokinetics and Antihypertensive Effects of Candesartan Cilexetil in Patients Undergoing Haemodialysis: An Open-Label, Single-Centre Study
Clinical Drug Investigation, 10/15/09
Antiviral Agents for Influenza: Molecular Targets, Concerns of Resistance, and New Treatment Options
Current Drug Targets, 10/23/09
Sponsor
Article Search
Sponsor